Dighe R R, Rojas F J, Birnbaumer L, Garber A J
J Clin Invest. 1984 Apr;73(4):1013-23. doi: 10.1172/JCI111286.
Glucagon receptor levels, glucagon-stimulated and other forms of adenylyl cyclase activity, and regulatory component activity of adenylyl cyclase were determined in hepatic plasma membranes of rats administered streptozotocin without and with insulin to produce varying degrees of hyperglycemia. Receptor levels were assayed by direct binding of the specific probe [125I-Tyr10]-iodoglucagon; regulatory component activity was assayed by the capacity to reconstitute stimulatory regulation in deficient membranes from cyc- S49 murine lymphoma cells. In rats given 150 mg streptozotocin, glucagon stimulation of adenylyl cyclase as well as basal, sodium fluoride, 5' guanylylimidodiphosphate [GMP-P(NH)P] and Mn-dependent activities were reduced 50%, glucagon receptor levels but not affinity were reduced 67%, and regulatory component activity was decreased 50%. In addition, alpha 1-adrenergic receptors and 5'-nucleotidase were similarly reduced in diabetes. However, specific ouabain-inhibitable Na+, K+, ATPase activity was not altered by streptozotocin treatment. The streptozotocin-induced changes were noted within 24 h and became maximal by 120 h after its administration. All of these decreases were partially reversed by in vivo insulin treatment. DNA, cytochrome c oxidase, glucose-6-phosphatase, and N-acetyl-beta-glucosaminidase content in hepatic plasma membrane preparations were not substantially different in diabetic as compared with control animals. The data demonstrate that glucagon-mediated regulation of cyclic AMP formation is deranged in insulin deficiency owing to a combined decrease in receptors, derangement of the coupling mechanism intervening between receptor and adenylyl cyclase, and possibly, an altered basal effector system. Some of these changes appear to reflect a "desensitization-like" phenomenon which may or may not be attributable to the hyperglucagonemia of diabetes mellitus. There also appears to be a concurrent generalized decrease in several but not all plasma membrane receptor and enzymatic proteins. This may be the result of a number of processes among which is the accelerated proteolysis of uncontrolled diabetes.
在给大鼠注射链脲佐菌素(分别给予或不给予胰岛素以产生不同程度的高血糖)后,测定其肝细胞膜中的胰高血糖素受体水平、胰高血糖素刺激的以及其他形式的腺苷酸环化酶活性,以及腺苷酸环化酶的调节成分活性。通过特异性探针[125I-Tyr10]-碘胰高血糖素的直接结合来测定受体水平;通过在来自cyc-S49鼠淋巴瘤细胞的缺陷膜中重建刺激调节的能力来测定调节成分活性。给予150mg链脲佐菌素的大鼠,胰高血糖素对腺苷酸环化酶的刺激以及基础、氟化钠、5'-鸟苷酰亚胺二磷酸[GMP-P(NH)P]和锰依赖性活性降低了50%,胰高血糖素受体水平而非亲和力降低了67%,调节成分活性降低了50%。此外,糖尿病大鼠的α1-肾上腺素能受体和5'-核苷酸酶也有类似程度的降低。然而,特异性哇巴因抑制的Na+、K+、ATP酶活性不受链脲佐菌素治疗的影响。链脲佐菌素诱导的变化在给药后24小时内即可观察到,并在120小时后达到最大值。体内胰岛素治疗可部分逆转所有这些降低。与对照动物相比,糖尿病大鼠肝细胞膜制剂中的DNA、细胞色素c氧化酶、葡萄糖-6-磷酸酶和N-乙酰-β-葡萄糖苷酶含量没有显著差异。数据表明,由于受体的联合减少、受体与腺苷酸环化酶之间偶联机制的紊乱以及可能改变的基础效应系统,胰岛素缺乏时胰高血糖素介导的环磷酸腺苷形成调节发生紊乱。其中一些变化似乎反映了一种“脱敏样”现象,这可能归因于也可能不归因于糖尿病的高胰高血糖素血症。还似乎同时存在几种(但不是所有)质膜受体和酶蛋白的普遍减少。这可能是多种过程的结果,其中包括未控制的糖尿病中加速的蛋白水解。